medigraphic.com
SPANISH

Medicina Crítica

  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • Policies
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2023, Number 8

<< Back Next >>

Med Crit 2023; 37 (8)

Standardization of PaO2 to PaCO2 in PaO2/FiO2 ratio as a predictor of mortality in patients with prone position and severe COVID-19

Márquez TCB, Gómez GN, Guerrero THE, Jiménez CC, Rodríguez CCE, Moreno RG
Full text How to cite this article 10.35366/115224

DOI

DOI: 10.35366/115224
URL: https://dx.doi.org/10.35366/115224

Language: Spanish
References: 19
Page: 666-671
PDF size: 220.60 Kb.


Key words:

COVID-19, acute respiratory distress syndrome, arterial oxygen pressure, mortality, critically ill patient.

ABSTRACT

Introduction: in 2019, severe acute respiratory syndrome (SARS-CoV-2) became universally known, caused by the coronavirus (COVID-19), which can manifest from asymptomatic forms or to clinical stages characterized by acute respiratory failure. pneumonia, septic shock and multiple organ failure, which require mechanical ventilation requirements. Mortality prediction markers are useful to prioritize patients at higher risk, improving the care of these patients. Objective: to evaluate the standardization of PaO2 to PaCO2 in the PaO2/FiO2 ratio as a predictor of hospital mortality in patients with prone position and invasive mechanical ventilation with acute respiratory failure by COVID-19. Material and methods: observational, retrospective, analytical cohort of patients admitted to the Intensive Care Unit service in the period from April to September 2020. Those with laboratory-confirmed SARS-CoV-2 infection; presence of consolidation and/or ground-glass opacities on chest X-ray and/or pulmonary computed tomography and presence of acute respiratory failure, requiring invasive mechanical ventilation, were included. Acute respiratory failure was considered to be present when PaO2 was < 60 mmHg with FiO2 0.21, excluding those in whom arterial blood gas records were not available before and after prone positioning. Demographic, clinical and blood gas data were recorded to obtain the PaO2 value standardized for PaCO2 (STPaO2), as well as mortality and days of mechanical ventilation in the unit. Results: a total of 74 patients were analyzed, with a mean age of 53.50 ± 12.77 years, with a predominance of men 63%, most patients were located in the groups of mild and moderate obesity according to their BMI 31 ± 4.71 kg/m2. Gasometric parameters before prone position were PaO2 of 81.94 ± 29.11 and PaCO2 of 44.62 ± 10.51 vs 97.37 ± 44.50 mmHg and 40.45 ± 8.51 mmHg respectively after being placed in the position. Reported STPaO2 pre-prone was 89.62 ± 39.77 vs 98.11 ± 45.02 post-prone. Mortality in this cohort was 44.6%. The population was then divided into two groups (survivors vs non-survivors), where no significant differences were found between the two groups for any of the blood gas parameters. After the patients were placed in prone position and arterial blood gas monitoring was performed, only for FiO2 and SpO2/FiO2 ratio a significant difference was found between survivors and non-survivors (p = 0.03 for both variables). In the ROC analysis FiO2 obtained an AUC 0.644 (95% CI 0.517-772) p = 0.034 to predict mortality and SpO2/FiO2 AUC 0.647 (95% CI 0.520-0.775) with a value of p = 0.03 to predict survival, in the postpronation period; STPaO2 did not obtain AUC with values of p < 0.05 neither before nor after the change of position to discriminate mortality. Conclusion: although the results in this study do not favor the standardization of PaO2 to PaCO2 in the PaO2/FiO2 ratio, it does suggest the use of FiO2 and SpO2/FiO2 ratio as predictors of mortality, specifically in those patients who developed respiratory failure under invasive mechanical ventilation by COVID-19.


REFERENCES

  1. Kumar S, Tao Q, Weaver S, Sanderford M, Caraballo-Ortiz MA, Sharma S, et al. An evolutionary portrait of the progenitor SARS-CoV-2 and its dominant offshoots in COVID-19 pandemic. Mol Biol Evol. 2021;38(8):3046-3059.

  2. Li J, Lai S, Gao GF, Shi W. The emergence, genomic diversity and global spread of SARS-CoV-2. Nature. 2021;600(7889):408-418.

  3. Hao YJ, Wang YL, Wang MY, Zhou L, Shi JY, Cao JM, et al. The origins of COVID-19 pandemic: a brief overview. Transbound Emerg Dis. 2022;69(6):3181-3197.

  4. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141-154.

  5. Davis JT, Chinazzi M, Perra N, Mu K, Pastore Y, Piontti A, et al. Cryptic transmission of SARS-CoV-2 and the first COVID-19 wave. Nature. 2021;600(7887):127-132.

  6. OMS. Panel de control de la enfermedad por coronavirus de la OMS (COVID-19) [Internet]. Ginebra: Organización Mundial de la Salud; 2023 [acceso 14/marzo/2023]. Disponible en: https://covid19.who.int/

  7. Gobierno de México, COVID-19 México [Internet]. México: 2023 [acceso 14/marzo/2023]. Disponible en: https://datos.covid-19.conacyt.mx/#COMNac

  8. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25(10):2000180.

  9. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021;93(3):1449-1458.

  10. Cascella M, Rajnik M, Aleem A, et al. Features, evaluation, and treatment of coronavirus (COVID-19) [Updated 2023 Aug 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available in: https://www.ncbi.nlm.nih.gov/books/NBK554776/

  11. Tzotzos SJ, Fischer B, Fischer H, Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit Care. 2020;24(1):516.

  12. Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson N, Caldwell E, et al. Acute respiratory distress syndrome. JAMA. 2012;307:2526-2533.

  13. Sartini S, Massobrio L, Cutuli O, Campodonico P, Bernini C, Sartini M, et al. Role of SatO2, PaO2/FiO2 ratio and PaO2 to predict adverse outcome in COVID-19: a retrospective, cohort study. Int J Environ Res Public Health. 2021;18(21):11534.

  14. Karbing DS, Kjaergaard S, Smith BW, Espersen K, Allerod C, Andreassen S, et al. Variation in the PaO2/FiO2 ratio with FiO2: mathematical and experimental description, and clinical relevance. Crit Care. 2007;11(6):R118.

  15. Villar J, Schultz MJ, Kacmarek RM. The LUNG SAFE: a biased presentation of the prevalence of ARDS! Crit Care. 2016;20(1):108.

  16. Mays EE. An arterial blood gas diagram for clinical use. Chest. 1973;63(5):793-800.

  17. Peniche Moguel KG, Sánchez Díaz JS, Castañeda Valladares E, Calyeca Sánchez MV, Díaz Gutiérrez SP, Pin Gutiérrez E. Ventilación mecánica en decúbito prono: estrategia ventilatoria temprana y prolongada en SIRA severo por influenza. Med Crít (Col Mex Med Crít). 2017;31(4):198-204.

  18. Accini Mendoza JL, Nieto Estrada VH, Beltrán López N, Ramos Bolaños E, Molano Franco D, Dueñas Castell C, et al. Actualización de la declaración de consenso en medicina crítica para la atención multidisciplinaria del paciente con sospecha o confirmación diagnóstica de COVID-19. Acta Colomb Cuid Intensivo. 2020;20(S1):1-112.

  19. Camargo Rubio RD. Triaje en la pandemia COVID-19: un abordaje con perspectiva de derechos humanos. Acta Colomb Cuid Intensivo. 2022;22(3):182-190.




Figure 1
Figure 2
Table 1
Table 2

2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Med Crit. 2023;37